HC-5404-Fu
Based on 1 Customer Validation
HC-5404-Fu is an orally active PERK inhibitor with an IC50 of 0.001 μM against human PERK. HC-5404-Fu blocks PERK activation induced by VEGFR-TKI and disrupts the adaptive stress response triggered by VEGFR-TKI. HC-5404-Fu enhances anti-angiogenic effects by inhibiting newly formed and mature tumor blood vessels in renal cell carcinoma models. HC-5404-Fu can be used in research related to renal cell carcinoma.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.92%
- CAS No.: 3034479-99-4
- Formule: C24H24F2N4O3.1/2C4H4O4
- Masse moléculaire:512.51
-
Stockage:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Kinase Inhibitor Library
HY-L009
-
Anti-Cancer Compound Library
HY-L025
-
Clinical Compound Library
HY-L026
-
Anti-Aging Compound Library
HY-L034
-
Endoplasmic Reticulum Stress Compound Library
HY-L054
-
Orally Active Compound Library
HY-L061
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Bioactive Compound Library Max
HY-L181
-
Clinical Compound Library Plus
HY-L026P
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Activité biologique
HC-5404-Fu (1 nM) potently and selectively inhibits recombinant PERK kinase activity in a cell-free biochemical assay with an IC50 of 1 nM, exhibiting >2,000-fold selectivity over other ISR kinases[1].
HC-5404-Fu (100-10,000 nM) demonstrates high kinome selectivity in a cell-free binding assay, with no off-target kinase interactions at 100 nM and only limited interactions at concentrations ≥1,000 nM[1].
HC-5404-Fu (1.5 nM-10 μM; 30-minute pretreatment, 4-hour co-incubation with tunicamycin) inhibits ER stress-mediated PERK activation and downstream ATF4 induction in HEK-293 cells with IC50 values of 23 nM (pPERK) and 88 nM (ATF4)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HEK-293 cells
-
Concentration:1.5 nM-10 μM
-
Incubation Time:30-minute pretreatment; 4-hour co-incubation with tunicamycin
-
Result:Inhibited tunicamycin-induced PERK autophosphorylation (pPERK Thr982) with an IC50 of 23 nmol/L.
Inhibited tunicamycin-induced ATF4 protein accumulation with an IC50 of 88 nmol/L.
HC-5404-Fu (3-30 mg/kg; p.o.; twice-a-day; 28 days) administered orally twice-a-day exerts dose-dependent single-agent antitumor activity in 786-O RCC xenografts, with 30 mg/kg twice-a-day achieving 48% TGI[1].
HC-5404-Fu (30-100 mg/kg; p.o.; twice-a-day; 48 days) administered orally twice-a-day exerts single-agent antitumor activity in Capan-2 pancreatic cancer xenografts, with 30 mg/kg twice-a-day achieving 50% TGI, a comparable effect to the higher 100 mg/kg twice-a-day dose[1].
HC-5404-Fu (30 mg/kg; p.o.; twice-a-day; 28 days) administered at 30 mg/kg orally twice-a-day enhances the antitumor efficacy of multiple VEGFR-TKI in 786-O RCC xenografts, inhibiting VEGFR-TKI-induced PERK activation and driving tumor regression when combined with axitinib or cabozantinib[1].
HC-5404-Fu (30 mg/kg; p.o.; twice-a-day; 28 to 30 days) administered at 30 mg/kg orally twice-a-day enhances the antitumor efficacy of sunitinib in both VHL-mutant (A-498) and VHL-wildtype (Caki-1) RCC xenografts, driving 22% tumor regression in A-498 models and 47% TGI in Caki-1 models[1].
HC-5404-Fu (30 mg/kg; p.o.; twice-a-day; 28 days) administered at 30 mg/kg orally twice-a-day enhances the antitumor efficacy of axitinib across a panel of 18 RCC PDX models, increasing the number of partial responses from 2 to 9 models, with 3 of 6 VHL-wildtype models showing improved response to the combination[1].
HC-5404-Fu (30 mg/kg; p.o.; twice-a-day; 28 days) administered at 30 mg/kg orally twice-a-day enhances the antitumor efficacy of the anti-VEGFR-2 antibody DC-101 in 786-O and A-498 RCC xenografts, achieving 82% and 78% TGI, respectively[1].
HC-5404-Fu (30 mg/kg; p.o.; twice-a-day; 28 days) administered at 30 mg/kg orally twice-a-day induces tumor regression (20% relative to baseline) when combined with axitinib in 786-O RCC xenografts that have progressed on axitinib monotherapy, while single-agent HC-5404 achieves 47% tumor growth inhibition relative to vehicle[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:athymic nude-Foxn1nu (6- to 8-week-old female; subcutaneously injected with 1×106 T-HEP3-PERK PERK-overexpressing human squamous cell carcinoma cells)[1]
-
Dosage:3 mg/kg; 30 mg/kg; 100 mg/kg
-
Administration:p.o.; single dose
-
Result:Induced 90% inhibition of pPERK in mouse pancreas at early timepoints post-dosing, with pPERK returning to basal levels by 12 hours (30 mg/kg single oral dose).
Maintained near-complete pPERK inhibition (>80% inhibition) in mouse pancreas for the first 12 hours post-dosing (100 mg/kg single oral dose).
Induced 90% pPERK inhibition in 786-O tumors at 1 hour, which returned to baseline by 8 hours (30 mg/kg single oral dose).
-
Animal Model:BALB/c nude (6- to 8-week-old female; subcutaneously injected with 5×106 786-O RCC cells)[1]
-
Dosage:3 mg/kg; 10 mg/kg; 30 mg/kg
-
Administration:p.o.; twice-a-day; 28 days
-
Result:Induced the greatest single-agent antitumor effect, resulting in 48% tumor growth inhibition (TGI) (30 mg/kg twice-a-day).
-
Animal Model:BALB/c nude (6- to 8-week-old female; subcutaneously injected with 5×106 786-O RCC cells)[1]
-
Dosage:30 mg/kg
-
Administration:p.o.; twice-a-day; 28 days
-
Result:Inhibited VEGFR-TKI-induced pPERK accumulation in 786-O tumors.
Resulted in tumor regression relative to baseline when combined with axitinib or cabozantinib.
Enhanced the level of TGI beyond that of either monotherapy when combined with lenvatinib or sunitinib.
Induced a dose-dependent accumulation of ATF4 downstream targets (ASNS, CBS, CTH) in 786-O tumors treated with sunitinib.
-
Animal Model:NMRI nu/nu (Crl:NMRI-Foxn1nu; 4- to 6-week-old female; subcutaneously implanted with fragments from 18 RCC patient-derived xenograft (PDX) tumors)[1]
-
Dosage:30 mg/kg
-
Administration:p.o.; twice-a-day; 28 days
-
Result:Resulted in 9 out of 18 PDX models achieving ≥50% tumor regression from baseline (partial responses) when combined with axitinib, compared with 2 out of 18 partial responses with axitinib monotherapy.
Led to 3 of 6 VHL-wildtype PDX models showing improved response to the combination treatment over axitinib monotherapy, with 2 achieving partial responses, 1 achieving 53% regression (partial response), 2 having stable disease, and 2 having progressive disease (with greater response to combination than monotherapies).
-
Animal Model:BALB/c nude (6- to 8-week-old female; subcutaneously injected with 5×106 786-O RCC cells, 5×106 A-498 RCC cells, or 6×106 Caki-1 RCC cells); NOD.SCID (6- to 8-week-old female; subcutaneously injected with 5×106 786-O RCC cells, 5×106 A-498 RCC cells, or 6×106 Caki-1 RCC cells)[1]
-
Dosage:30 mg/kg
-
Administration:p.o.; twice-a-day; 28 days
-
Result:Resulted in 82% TGI in 786-O xenografts when combined with DC-101, improving the effects of each monotherapy.
Resulted in 78% TGI in A-498 xenografts when combined with DC-101, improving the effects of each monotherapy.
Induced only 24% TGI in Caki-1 xenografts when combined with DC-101, with no significant combination benefit observed.
-
Animal Model:BALB/c nude (6- to 8-week-old female; subcutaneously injected with 5×106 786-O RCC cells; tumors progressed on axitinib monotherapy for 14 days)[1]
-
Dosage:30 mg/kg
-
Administration:p.o.; twice-a-day; 28 days
-
Result:Inhibited tumor growth by 47% relative to vehicle as single-agent.
Resulted in an average 20% tumor regression relative to baseline when combined with axitinib.
Reduced the proportion of Meca32+ endothelial cells, CD31+SMA+ mature blood vessels, and NG2+/MCAM+ pericytes in tumor sections beyond the effects of axitinib monotherapy when combined with axitinib.
Chemical Information
-
CAS No. 3034479-99-4
-
Appearance Solid
-
Masse moléculaire 512.51
-
Formule C24H24F2N4O3.1/2C4H4O4
-
Color White to off-white
-
SMILES
CC(C)NC(C1=CC(C2=CC=C(C=C2C)NC([C@@H](C3=CC(F)=CC(F)=C3)O)=O)=CN=C1N)=O.O=C(O)/C=C/C(O)=O.[1/2]
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Solvant et solubilité
DMSO : 100 mg/mL (195.12 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5 mg/mL (9.76 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (284 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9512 mL | 9.7559 mL | 19.5118 mL | 48.7795 mL |
| 5 mM | 0.3902 mL | 1.9512 mL | 3.9024 mL | 9.7559 mL | |
| 10 mM | 0.1951 mL | 0.9756 mL | 1.9512 mL | 4.8780 mL | |
| 15 mM | 0.1301 mL | 0.6504 mL | 1.3008 mL | 3.2520 mL | |
| 20 mM | 0.0976 mL | 0.4878 mL | 0.9756 mL | 2.4390 mL | |
| 25 mM | 0.0780 mL | 0.3902 mL | 0.7805 mL | 1.9512 mL | |
| 30 mM | 0.0650 mL | 0.3252 mL | 0.6504 mL | 1.6260 mL | |
| 40 mM | 0.0488 mL | 0.2439 mL | 0.4878 mL | 1.2195 mL | |
| 50 mM | 0.0390 mL | 0.1951 mL | 0.3902 mL | 0.9756 mL | |
| 60 mM | 0.0325 mL | 0.1626 mL | 0.3252 mL | 0.8130 mL | |
| 80 mM | 0.0244 mL | 0.1219 mL | 0.2439 mL | 0.6097 mL | |
| 100 mM | 0.0195 mL | 0.0976 mL | 0.1951 mL | 0.4878 mL |
HC-5404-Fu Related Classifications
HY-157231A Related Classifications
Powered by Bioz